WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that, after a distinguished 28-year career, including over 6 years at Disc, Brian MacDonald, MB, ChB, PhD, will be retiring from his role as Chief Innovation Officer. Dr. MacDonald plans to stay involved with Disc, transitioning from his current role to become Chair of Disc’s Scientific Advisory Board.
“We are incredibly grateful for all of Brian’s exceptional contributions and leadership over the past 6 years. As the Founder and original CEO of Disc, Brian was instrumental in developing the company’s strong foundation and his visionary leadership has been a driving force behind Disc’s growth and the innovation that defines our organization,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer. “We are thrilled that Brian has agreed to remain involved with Disc and look forward to his continued leadership as part of the Scientific Advisory Board. On behalf of the Board and the entire Disc team, I extend a heartfelt thanks to Brian for his unwavering commitment to Disc and wish him all the best in his retirement.”
“It has been an immense privilege to be a part of the leadership at Disc, which has allowed me to oversee the remarkable growth and substantial achievements of the company since its inception,” said Dr. MacDonald. “I am proud of all Disc has accomplished thus far and am excited to remain a part of Disc’s continued growth towards becoming a leading hematology company.”
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
